Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 26 Oct 2026
Standard addition

ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.

Detecting circulating tumor DNA after lung cancer surgery may help predict which patients remain at high relapse risk.

Patients with resectable non-small cell lung cancer (NSCLC) remain at high risk of relapse despite perioperative treatment 1-3 . Here, we present the first report of prespecified secondary endpoints of event-free survival (EFS) and circulating tumour DNA (ctDNA) clearance, and exploratory analyses of associations between ctDNA dynamics and clinical outcomes.

What the study was

Study design
Randomized clinical trial
Population
Patients with resectable non-small cell lung cancer (NSCLC) remain at high risk of relapse despite perioperative treatment 1-3 .
Category
Early Detection
Maturity
Validated
Journal
Nature

Why it surfaced

Randomized clinical trial with a PubMed abstract reviewed; the 7/10 score reflects conservative novelty, relevance, design-quality, and population/unmet-need assessment.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.